Patents by Inventor Xinrong Tian

Xinrong Tian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10604531
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: March 31, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Steven David Knight, Louis Vincent Lafrance, III, Xinrong Tian
  • Publication number: 20190092785
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: May 1, 2017
    Publication date: March 28, 2019
    Inventors: Steven David KNIGHT, Louis Vincent LAFRANCE, III, Xinrong TIAN
  • Publication number: 20180162845
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: June 30, 2016
    Publication date: June 14, 2018
    Inventors: James A. BRACKLEY, III, Alan Peterson GRAVES, III, Steven David KNIGHT, Kenneth C. MCNULTY, Kenneth Allen NEWLANDER, Xinrong TIAN
  • Publication number: 20170334891
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: October 28, 2015
    Publication date: November 23, 2017
    Applicant: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Steven David KNIGHT, Kenneth Allen NEWLANDER, Xinrong TIAN
  • Patent number: 9790212
    Abstract: This invention relates to novel compounds according to Formula (III)(a) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 17, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • Patent number: 9649307
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: May 16, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: William Henry Miller, Xinrong Tian, Sharad Kumar Verma
  • Publication number: 20170029412
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: October 13, 2016
    Publication date: February 2, 2017
    Inventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN
  • Publication number: 20170015666
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: March 6, 2015
    Publication date: January 19, 2017
    Inventors: William Henry MILLER, Stuart Paul ROMERIL, Xinrong TIAN, Sharad Kumar VERMA
  • Patent number: 9505745
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: November 29, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • Publication number: 20160296518
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Application
    Filed: June 20, 2016
    Publication date: October 13, 2016
    Inventors: William Henry MILLER, Xinrong TIAN, Sharad Kumar VERMA
  • Patent number: 9402836
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: August 2, 2016
    Assignee: GlaxoSmithKline LLC
    Inventors: James Brackley, III, Joelle Lorraine Burgess, Seth Wilson Grant, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
  • Patent number: 9346840
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: May 24, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Neil W. Johnson, Jiri Kasparec, Meagan B. Rouse, Xinrong Tian, William Henry Miller, Dominic Suarez
  • Publication number: 20160102083
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: April 25, 2014
    Publication date: April 14, 2016
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN
  • Publication number: 20150313887
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Application
    Filed: July 9, 2015
    Publication date: November 5, 2015
    Inventors: James BRACKLEY, III, Joelle Lorraine Burgess, Seth Wilson Grant, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
  • Patent number: 9114141
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: August 25, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: William Henry Miller, Xinrong Tian, Shared Kumar Verma
  • Patent number: 9073924
    Abstract: Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: July 7, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Joelle Lorraine Burgess, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Dominic Suarez, Xinrong Tian, Sharad Kumar Verma
  • Publication number: 20150141436
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 21, 2015
    Inventors: William Henry Miller, Xinrong Tian, Sharad Kumar Verma
  • Patent number: 9018382
    Abstract: Herein are disclosed indazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: April 28, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Celine Duquenne, Neil Johnson, Steven D. Knight, Louis LaFrance, William H. Miller, Kenneth Newlander, Stuart Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
  • Patent number: 8975291
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: March 10, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: James Brackley, III, Joelle Lorraine Burgess, Seth Grant, Neil Johnson, Steven D. Knight, Louis Lafrance, William H. Miller, Kenneth Newlander, Stuart Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
  • Publication number: 20140371176
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Application
    Filed: September 3, 2014
    Publication date: December 18, 2014
    Inventors: Neil W. Johnson, Jiri Kasparec, Meagan B. Rouse, Xinrong Tian